Regenxbio (RGNX) Change in Accured Expenses (2014 - 2025)

Regenxbio's Change in Accured Expenses history runs 12 years deep, the most recent figure standing at $45000.0 for Q4 2025.

• In Q4 2025, Change in Accured Expenses rose 103.88% year-over-year to $45000.0; the TTM figure through Dec 2025 stood at $229000.0 (up 108.78% YoY), while the FY2025 annual figure was $229000.0, up 108.78% from the prior year.
• Change in Accured Expenses for Q4 2025 stood at $45000.0, down from $3.2 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $33.5 million in Q3 2022, with the low at -$33.6 million in Q4 2022.
• The 5-year median for Change in Accured Expenses is $76000.0 (2023), against an average of -$1.5 million.
• Peak annual rise in Change in Accured Expenses reached 111883.33% in 2022, while the deepest fall reached 11631.96% in 2022.
• Regenxbio's Change in Accured Expenses stood at $291000.0 in 2021, then tumbled by 11631.96% to -$33.6 million in 2022, then soared by 100.36% to $121000.0 in 2023, then tumbled by 1059.5% to -$1.2 million in 2024, then soared by 103.88% to $45000.0 in 2025.
• Business Quant data shows RGNX's Change in Accured Expenses at $45000.0 in Q4 2025, $3.2 million in Q3 2025, and $11.5 million in Q2 2025.